NICE gives Aubagio the nod

Share this article:

The UK's price watchdog NICE has approved Sanofi's oral MS medication Aubagio for adults with relapsing-remitting multiple sclerosis, which means the National Health Service will begin funding the drug within the next three months.

Wednesday's thumbs-up is a re-tread. NICE told Sanofi in September that Sanofi had to provide cost-effectiveness data that would indicate the drug deserves a space on the formulary compared to what's already on the market. The drug costs around $22,500 per patient per year in the UK.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.